Operation Warp Speed funding
GPTKB entity
Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
government funding program
|
| gptkbp:announced |
gptkb:U.S._Department_of_Health_and_Human_Services
2020 |
| gptkbp:endDate |
2021
|
| gptkbp:fundedBy |
gptkb:Emergent_BioSolutions
gptkb:Moderna gptkb:Pfizer gptkb:U.S._federal_government gptkb:AstraZeneca gptkb:Johnson_&_Johnson gptkb:Sanofi gptkb:Regeneron gptkb:Novavax clinical trials over $18 billion manufacturing capacity expansion vaccine distribution infrastructure |
| https://www.w3.org/2000/01/rdf-schema#label |
Operation Warp Speed funding
|
| gptkbp:partOf |
gptkb:Operation_Warp_Speed
|
| gptkbp:purpose |
accelerate COVID-19 vaccine development
accelerate COVID-19 diagnostic development accelerate COVID-19 therapeutic development |
| gptkbp:bfsParent |
gptkb:Moderna,_Inc.
gptkb:Novavax |
| gptkbp:bfsLayer |
6
|